Welcome

Hematology Franchise Overview

Review of Key Clinical Data Presented at ASH: Hemlibra, mosun, glofit, cevostamab

Presentation of POLARIX data

Q&A

Karl Mahler, Head of Investor Relations

Peter Ahnesorg, Franchise Head Hematology

Charles Fuchs, Senior Vice President - Global Head Of Oncology And Hematology Product Development

Franck Morschhauser, MD, PhD, Professor of Hematology, University of Lille; President of LYSA, LYSARC